Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at William Blair increased their Q4 2018 earnings per share estimates for Gilead Sciences in a report issued on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of $1.88 per share for the quarter, up from their previous estimate of $1.78. William Blair has a “Buy” rating on the stock.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the business earned $2.70 EPS. Gilead Sciences’s revenue for the quarter was down 18.7% compared to the same quarter last year.

A number of other research analysts have also commented on GILD. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Thursday, October 19th. Leerink Swann upped their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research note on Thursday, October 19th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $87.04.

Gilead Sciences (GILD) opened at $79.32 on Monday. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a market cap of $103,613.26, a PE ratio of 22.79, a P/E/G ratio of -1.77 and a beta of 1.22. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is 59.77%.

In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP James R. Meyers sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the sale, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 358,333 shares of company stock valued at $28,066,908. 1.30% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the stock. Welch Investments LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $144,000. Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences in the 2nd quarter valued at approximately $147,000. 76.47% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/02/12/q4-2018-eps-estimates-for-gilead-sciences-inc-raised-by-william-blair-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.